This diagnosis was subsequently confirmed by ADAMTS13 testing, which revealed severely reduced enzymatic activity and elevated inhibitor titers, consistent with acquired immune-mediated TTP. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.